EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen access · CC BY 4.0

Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial

Seladelpar verbesserte Juckreiz, juckreizbedingte Schlafstörung und Fatigue-Maße bei Patient:innen mit primärer biliärer Cholangitis und Pruritus in der Phase-3-RESPONSE-Studie

Cynthia Levy, David E J Jones, Marlyn J Mayo, Christopher L Bowlus, Kris V Kowdley, Gideon M Hirschfield, Jie Liu, Caroline Burk, Susheela Carroll, Daria B Crittenden, Andreas E Kremer iD

Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (1) · 23-35

DOI: 10.1111/apt.70630 ↗

Auf einen Blick

In der Phase-3-RESPONSE-Studie verbesserte Seladelpar Juckreiz, juckreizbedingte Schlafstörung und Fatigue-Maße bei Patient:innen mit PBC und Pruritus. Der Effekt war gegenüber Placebo vorteilhaft.

Fragestellung

Welche Auswirkungen hat Seladelpar auf Juckreiz, juckreizbedingte Schlafstörung und Fatigue bei Patient:innen mit primärer biliärer Cholangitis und Pruritus?

Methode

Phase-3-RESPONSE-Studie; Patient:innen mit PBC und unzureichendem Ansprechen oder Unverträglichkeit von Ursodeoxycholsäure wurden 2:1 zu Seladelpar 10 mg oder Placebo für 12 Monate randomisiert.

Ergebnisse

Bei Baseline-NRS ≥ 4 verbesserte sich der mittlere NRS unter Seladelpar von moderat zu mild, nicht unter Placebo. Juckreizverteilung, Schlafstörung und Fatigue-Maße verbesserten sich; Patient:innen ohne Juckreiz blieben häufiger ohne Juckreiz.

Schlussfolgerung der Autor:innen

Zusätzlich zum anticholestatischen Effekt verbesserte Seladelpar die Schwere und Verteilung des Pruritus, die juckreizbedingte Schlafstörung und Fatigue-Maße mit klinisch relevanten Verbesserungen.

Kernaussagen

  • Seladelpar verbesserte den Juckreiz bei PBC mit Pruritus
  • Juckreizbedingte Schlafstörung besserte sich unter Seladelpar
  • Fatigue-Maße verbesserten sich gegenüber Placebo bei schwerem Juckreiz

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-04-03. Written by Cynthia Levy and 10 co-authors. Institution: Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA. Major MEDLINE topics: Pruritus, Liver Cirrhosis, Biliary, Fatigue, Sleep Wake Disorders. Cited 7 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY 4.0). Funded by: Gilead Sciences, Inc., Gilead Sciences.

Auf einen BlickAbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Pruritus and fatigue impose a significant burden on patient quality of life in primary biliary cholangitis (PBC). In the Phase 3 RESPONSE trial (NCT04620733), seladelpar, a potent and selective PPARδ agonist, significantly improved markers of cholestasis and pruritus.

Aims

Here, we provide additional details on the effects of seladelpar on pruritus and quality of life.

Methods

In RESPONSE, patients with PBC and an inadequate response or intolerance to ursodeoxycholic acid were randomised 2:1 to seladelpar 10 mg or placebo for 12 months. Changes in severity of pruritus by the numeric rating scale (NRS) and changes in 5‐D Itch and PBC‐40 in patients with moderate to severe itch (NRS ≥ 4), severe itch (NRS ≥ 7) and clinically significant itch (PBC‐40 itch ≥ 7) at baseline were evaluated.

Results

In patients with baseline NRS ≥ 4, mean NRS improved from the moderate to mild range with seladelpar, but not placebo. Bodily distribution of itch was reduced with seladelpar based on the 5‐D itch distribution domain. Itch‐related sleep disturbance was consistently improved with seladelpar across populations, and measures of fatigue were improved versus placebo in patients with severe itch at baseline. Patients without itching tended to remain free from itching with seladelpar, consistent with fewer adverse events of pruritus with seladelpar versus placebo.

Conclusion

In addition to an established anticholestatic effect, seladelpar improved pruritus severity and distribution, itch‐related sleep disturbance and measures of fatigue in patients with PBC and pruritus, indicating clinically relevant improvements in itch and other quality of life benefits.

Subjects

MeSH terms (MEDLINE)

PruritusLiver Cirrhosis, BiliaryFatigueSleep Wake DisordersHumansFemaleMiddle AgedQuality of LifeMaleSeverity of Illness IndexTreatment OutcomeAgedDouble-Blind MethodAdult

Author keywords

cholestatic liver diseaseliveroutcomes researchprimary biliary cholangitis

Authors and institutions

  • Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Division of Digestive Health and Liver Diseases, University of Miami School of Medicine, Miami, Florida, USA.
  • Department of Medical Sciences, NIHR Newcastle Biomedical Research Centre, Newcastle, UK.
  • Division of Digestive and Liver Diseases, University of Texas SW Medical Center, Dallas, Texas, USA.
  • Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California, USA.
  • Liver Institute Northwest, Seattle, WA, USA.

ORCID profiles: Andreas E Kremer

Funding

  • Gilead Sciences, Inc.
  • Gilead Sciences

Cite

APA

Levy, C., Jones, D. E. J., Mayo, M. J., Bowlus, C. L., Kowdley, K. V., Hirschfield, G. M., Liu, J., Burk, C., Carroll, S., Crittenden, D. B., & Kremer, A. E. (2026). Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial. Alimentary Pharmacology & Therapeutics, 64(1), 23-35. https://doi.org/10.1111/apt.70630

Vancouver

Levy C, Jones DEJ, Mayo MJ, Bowlus CL, Kowdley KV, Hirschfield GM, et al. Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial. Alimentary Pharmacology & Therapeutics. 2026;64(1):23-35. doi:10.1111/apt.70630

BibTeX
@article{Levy2026,
  author = {Levy, Cynthia and Jones, David E J and Mayo, Marlyn J and Bowlus, Christopher L and Kowdley, Kris V and Hirschfield, Gideon M and Liu, Jie and Burk, Caroline and Carroll, Susheela and Crittenden, Daria B and Kremer, Andreas E},
  title = {Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {1},
  pages = {23--35},
  doi = {10.1111/apt.70630}
}
Start for free →